RxDoctor Payments Data

Kyra Laupp

Family · Greenville, NCNPI 1023781184

Payments from drug & device makers

$8,121in general payments, 2019–2025

Across 379 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$677
  • Novartis$670
  • Pfizer$500
  • Johnson & Johnson$466
  • Astellas Pharma US Inc$427
  • AbbVie$406
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,31890%
  • Education$80310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation32$677
Novartis35$670
Pfizer26$500
Johnson & Johnson(2 entities)22$466
Astellas Pharma US Inc11$427
AbbVie11$406
Bayer17$332
Merck14$267
GSK15$242
AstraZeneca(2 entities)11$237
Puma Biotechnology, Inc.12$199
Sanofi5$189
Takeda Pharmaceuticals U.S.A., Inc.8$182
Celltrion USA Inc.2$179
Lilly USA, LLC10$177
Amgen10$169
Dendreon Pharmaceuticals LLC8$161
Taiho Oncology, Inc.6$153
Pharmacyclics LLC, An Abbvie Company10$148
Karyopharm Therapeutics Inc.6$141
Eisai Inc.7$127
Gilead2$106
Regeneron Healthcare Solutions, Inc.3$101
Seagen Inc.6$98
Genentech USA, Inc.5$93
E.r. Squibb & Sons, L.L.C.4$85
Sanofi-aventis U.S. LLC1$81
Blue Earth Diagnostics3$74
Pharmacosmos Therapeutics Inc.4$74
Spectrum Pharmaceuticals Inc.3$69
Beigene USA, Inc.3$69
Daiichi Sankyo Inc.3$67
Novocure Inc.3$66
Servier Pharmaceuticals LLC3$66
Adaptive Biotechnologies Corporation3$65
Ipsen Biopharmaceuticals, Inc3$64
ADC Therapeutics America, Inc.4$55
Organon5$53
EMD Serono, Inc.3$50
G1 Therapeutics, Inc.2$45
Bristol Myers Squibb2$43
Tersera Therapeutics LLC3$41
Exelixis Inc.2$39
Jazz Pharmaceuticals Inc.2$35
Genmab U.S., Inc.2$34
Apellis Pharmaceuticals, Inc.2$34
AVEO Pharmaceuticals, Inc.1$31
Deciphera Pharmaceuticals Inc.2$31
Coherus Oncology, Inc.1$29
Morphosys, US Inc.2$28
Tempus AI, Inc1$27
Stemline Therapeutics Inc.1$26
Boehringer Ingelheim1$25
Mirati Therapeutics, Inc.1$24
Legend Biotech USA Inc.1$24
Array Biopharma Inc1$23
Agios Pharmaceuticals, Inc.1$20
Sobi, Inc1$19
Pharmaessentia USA Corporation1$19
Progenics Pharmaceuticals, Inc.1$16

How this compares

$8,121 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,257
Medicare patients
30
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$18,643
OxycontinOxycodone Hcl11$10,033
Oxycodone Hcl37$608
Letrozole13$512
Dexamethasone11$421
Prochlorperazine Maleate19$197
Gabapentin14$165
Anastrozole18$142
Ondansetron Hcl21$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$500$18,64315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →